Findings

What do systematic reviews say?

1,501 questions · 1,558 findings · 115 reviews · Vascular

Sort:Best matchNewestHighest certainty Download CSV

No studies found 346 · 22.2%GRADE not reported 90 · 5.8%Very low 281 · 18%Low 477 · 30.6%Moderate 313 · 20.1%High 51 · 3.3%

Sclerotherapy vs placebo

Recurrence · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

Resolution or improvement of telangiectasias ( · people with telangiectasias and reticular veins

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 710 participants
Low

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins

Laser plus sclerotherapy showed no clear difference in adverse events ‐ Hyperpigmentation ( compared with sclerotherapy (low certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 0.83 [0.35, 1.99]
2 studies · 656 participants
Low

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

Adverse events ‐ matting ( · people with telangiectasias and reticular veins

Laser plus sclerotherapy showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (low certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 0.83 [0.21, 3.28]
2 studies · 656 participants
Low

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

Pain ( · people with telangiectasias and reticular veins

Laser plus sclerotherapy may leads to higher pain ( compared with sclerotherapy (low certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 2.44 [1.69, 3.55]
1 study · 596 participants
Low

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

Recurrence · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

Time to resolution · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

Quality of life · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sclerotherapy (hypertonic glucose plus polidocanol) vs sclerotherapy (hypertonic glucose)

Resolution or improvement of telangiectasias ( · people with telangiectasias and reticular veins

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 191 participants
Moderate

Sclerotherapy (hypertonic glucose plus polidocanol) vs sclerotherapy (hypertonic glucose)

Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins

Sclerotherapy (hypertonic glucose plus polidocanol) showed no clear difference in adverse events ‐ hyperpigmentation ( compared with sclerotherapy (hypertonic glucose) (moderate certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 0.79 [0.62, 1.01]
2 studies · 191 participants
Moderate

Sclerotherapy (hypertonic glucose plus polidocanol) vs sclerotherapy (hypertonic glucose)

Adverse events ‐ matting ( · people with telangiectasias and reticular veins

Sclerotherapy (hypertonic glucose plus polidocanol) showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (hypertonic glucose) (moderate certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 0.78 [0.51, 1.2]
2 studies · 191 participants
Moderate

Sclerotherapy vs placebo

Time to resolution · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sclerotherapy (hypertonic glucose plus polidocanol) vs sclerotherapy (hypertonic glucose)

Pain ( · people with telangiectasias and reticular veins

Sclerotherapy (hypertonic glucose plus polidocanol) showed no clear difference in pain ( compared with sclerotherapy (hypertonic glucose) (moderate certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 1.02 [0.83, 1.24]
2 studies · 191 participants
Moderate

Sclerotherapy (hypertonic glucose plus polidocanol) vs sclerotherapy (hypertonic glucose)

Recurrence · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sclerotherapy (hypertonic glucose plus polidocanol) vs sclerotherapy (hypertonic glucose)

Time to resolution · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sclerotherapy (hypertonic glucose plus polidocanol) vs sclerotherapy (hypertonic glucose)

Quality of life · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sclerotherapy plus compression vs sclerotherapy (any sclerosant)

Resolution or improvement of telangiectasias ( · people with telangiectasias and reticular veins

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 196 participants
Moderate

Sclerotherapy plus compression vs sclerotherapy (any sclerosant)

Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins

Sclerotherapy plus compression showed no clear difference in adverse events ‐ hyperpigmentation ( compared with sclerotherapy alone (moderate certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 0.93 [0.41, 2.07]
2 studies · 196 participants
Moderate

Sclerotherapy plus compression vs sclerotherapy (any sclerosant)

Adverse events ‐ matting ( · people with telangiectasias and reticular veins

Sclerotherapy plus compression showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy alone (low certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 1.84 [0.17, 19.62]
1 study · 96 participants
Low

Sclerotherapy plus compression vs sclerotherapy (any sclerosant)

Pain · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found